“I see Alzheimer’s disease as one of the last great frontiers in medicine,” said Remi Barbier, President & CEO. “It’s clear to me these patients need new and more simplified treatment options. In 2024 and beyond, we’ll continue to try to make a meaningful difference in the lives of people who suffer from Alzheimer’s disease. I believe our Phase 3 program of simufilam in Alzheimer’s will reach important milestones in 2024, particularly in patients with mild disease.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SAVA:
- Short Report: Bears squeeze MicroStrategy as shares track bitcoin higher
- Cassava Sciences Announces Key Development with Press Release
- Cassava Sciences call volume above normal and directionally bullish
- No Decline in Cognition Scores in Patients with Mild Alzheimer’s Disease Who Received Simufilam Continuously For 24 Months
- Cassava Sciences reports results of two-year study of simufilam
